Product Introduction:
14 types of high-risk HPV, as classified by WHO (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) are detected by this kit.
This product can detect the 2 most common high-risk HPV types (HPV16/18), and separately another 12 high-risk HPV types, which in total cause 70% of cervical cancers. The results of this test have increased clinical significance for the diagnosis and management guidance of cervical cancer patients.
Product advantages:
1. No special requirements for experimental conditions
The test kit adopts a hybridization capture-chemiluminescence method, which does not require nucleic acid extraction and amplification. The product is suitable for use in hospitals of all levels to carry out detection in-house.There is no specific need for a external gene amplification laboratory.
2. Avoids false negative results
- The use of 14 types of RNA probes avoids false negative results that may arise due to missing HPV L1 region
- The product does not require DNA extraction, avoiding false negatives due to extraction loss
- The negative predictive value is >99.9%
- Excellent repeatability of test results
3. Avoids false positive results
- The product does not require nucleic acid amplification, effectively avoiding false positives caused by environmental factors
- The WHO recommended cut-off value (1.0pg/mL) ensures high specificity for identifying high-grade cervical intraepithelial neoplasia (CIN)
- There is no cross-reactivity with low-risk HPV, ensuring that positive results are associated with clinical lesions
Packaging specifications: 48 tests/box, 96 tests/box
Storage condition: 2 ~ 8℃, avoid freezing
Validity period: 12 months